Gufic Biosciences Ltd.

GUFICBIO NSE Healthcare Pharmaceuticals
₹425.10
+0.58%
Delayed · cached 15 min

Fair value analysis

GUFICBIO
Gufic Biosciences Ltd.
HealthcarePharmaceuticals
₹422.65
Close used for this calculation
₹168.04Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
28/100
Profitability6/25
Returns6/25
Balance Sheet14/25
Efficiency2/25
Growth0/25
Weak
Quality radar
28Prof.6/25Ret.6/25Eff.2/25B.Sht14/25Growth0/25

Consensus fair value

₹168.04
Above FV
▼ -60.2% against the close used
Model range ₹26.01 – ₹228.48
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹26.01Fair value₹168.04Bull₹228.48
FairClose
52-week traded range
52W low ₹273.5052W high ₹444.90

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Gufic Biosciences Ltd. closed at ₹422.65, 151.5% above the consensus fair value of ₹168.04 drawn from 7 valuation models.

Financial DNA score 28/100 — Weak. P/E of 58.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹26.01
-93.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹104.25
-75.3%
√(22.5 × EPS × BVPS)
EPS=6.4, BVPS=75.47 · outside Graham range (P/E 58, P/B 5.6) — asset-light, treat as a rough floor
P/E Fair Value
₹228.48
-45.9%
EPS × 35.7x (sector P/E)
EPS=6.4, Sector P/E=35.7x
EV/EBITDA
₹140.29
-66.8%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=1.82B
Book Value (P/B)
₹76.55
-81.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=75.47, ROE=10.1%, g=3%, r=10%
Reverse DCF
₹422.65
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 23.3% | Historical: 0%
Margin of Safety
₹89.69
-78.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=119.58, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.